Propeller Health Receives FDA Clearance to Connect Patients Using the Symbicort® Inhaler to its Digital Health Platform

Propeller Health, a digital health company dedicated to the management of asthma and COPD, announced that it has received 501(k) clearance from the FDA to connect patients using AstraZeneca’s Symbicort Inhaler to its digital health platform.

The Propeller Health platform already connects to the majority of inhalers used by asthma and COPD patients, including those manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Orion, as well as many generic equivalent inhalers.

Propeller is a tool that helps asthma and COPD patients manage their condition in partnership with their healthcare provider. Propeller sensors attach to patients’ existing inhalers and deliver insights on medication use to the Propeller smartphone app, which patients can then share with their clinician to help inform their treatment plan.

Clinical studies have shown that the Propeller Health platform increases asthma control by up to 63 percent, increases medication adherence by up to 58 percent, reduces asthma-related emergency department visits and hospitalizations by as much as 57 percent, and reduces COPD-related healthcare utilization by as much as 35 percent.

“Our partnership with AstraZeneca will give respiratory patients a tool to help manage their condition and increase their medication adherence, a critical factor in keeping people out of the hospital,” said Propeller Health Co-founder and CEO David Van Sickle. “This is an important step in transforming the way people receive preventive care, enabling self-management from home and ensuring that providers have the bandwidth to focus on high-risk patients.

Read the original press release here.

See further coverage in: